Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: A prospective phase II study

Gastric Cancer

Volumn 6, Issue 3, 2003, Pages 159-167

  Ott, Katja ^a   Sendler, Andreas ^a   Becker, Karen ^b   Dittler, Hans Joachim ^a   Helmberger, Hermann ^a   Busch, Raimonde ^c   Kollmannsberger, Christian ^a   Siewert, J Rüdiger ^a   Fink, Ulrich ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adenocarcinoma; Neoadjuvant chemotherapy; Stomach

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EMBOLISM; EPISTAXIS; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN MANIFESTATION; STOMACH CANCER; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0042175567     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-003-0245-4     Document Type: Article

References (40)

1. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583-92.
2. Siewert JR, Böttcher K, Stein H, Roder JD, and the German Gastric Carcinoma Study Group. Relevant prognostic factors in gastric cancer. Ann Surg 1998;228:449-61.
3. Kelsen D. Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1998;23:379-89.
4. Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg 1995;19:216-20.
5. Lowy AM, Leach SD. Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer. Oncology (Huntingt) 1999;13:121-30.
6. Leichman L, Silberman H, Leichman CG, Spears CP, Ray M, Muggia FM, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 1992;10:1933-42.
7. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993;85:1839-44.
8. Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, et al. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer 1995;31A: 665-70.
9. Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma - a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994; 30A:1269-75.
10. Fink U, Stein HJ, Schuhmacher C, Wilke HJ. Neoadjuvant chemotherapy for gastric cancer: update. World J Surg 1995;19:509-16.
11. Alexander HR, Grem JL, Hamilton JM, Pass HI, Hong M, Fraker DL, et al. Thymidilate synthase protein expression: association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and esophageal adenocarcinoma. Cancer J 1995;1:49-54.
12. Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trail of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996;14:1818-28.
13. Siewert JR, Sendler A. The current management of gastric cancer. Adv Surg 1999;33:69-93.
14. Kelsen D, Karpeh M, Schwartz G, Christman K. Neoadjuvant and postoperative chemotherapy for high risk patients with gastric cancer (abstract). Proc Am Soc Clin Oncol 1994;13:195.
15. Siewert JR, Fink U, Sendler A, Becker K, Böttcher K, Feldmann HJ, et al. Gastric cancer. Curr Probl Surg 1997;43:837-937.
16. Wilke H, Korn M, Köhne C, Fink U, Preusser P, Vanhoefer U, et al. Phase II results of weekly infusional high-dose 5-FU (HD-5-FU) plus folinic acid (FA) and biweekly cisplatin (C) for advanced gastric cancer (abstract). Ann Oncol 1996;7 (Suppl 5):46.
17. Sendler A. Response evaluation - pathway for accurate indications development. Kongressbd Dtsch Ges Chir Kongr 2001;118: 169-71.
18. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999;17:2403-11.
19. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. Tokyo: Kanehara; 1995, 1: pp. 1-35.
20. UICC. TNM classification of malignant tumors. 4th Ed. Berlin Heidelberg, New York: Springer-Verlag; 1997.
21. American Joint Committee on Cancer. Manual for staging of cancer. 2nd. Ed, Philadelphia: JB Lippincott; 2000.
22. Becker K, Mueller J, Fink U, Busch R, Siewert JR, Höfler H. Morphologische Responseevaluierung beim neoadjuvant chemotherapierten Magenkarzinom. Verh Dtsch Ges Pathol 2000;84: 164-74.
23. Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995;82:1248-52.
24. Crookes P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 1997; 79:1767-75.
25. Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA, et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 1999;35:558-62.
26. Kang YK, Choi DW, Im YH, Kim CM, Lee JI, Moon NM, et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer (abstract). Proc Am Soc Clin Oncol 1996;15:215.
27. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989;7:1318-26.
28. Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001;91:918-27.
29. Poorter RL, Lauw FN, Bemelman WA, Bakker PJ, Taat CW, Veenhof CH. Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. Eur J Cancer 1996;32A:2262-6.
30. Loreto MF, De Martinis M, Corsi MP, Modesti M, Ginaldi L. Coagulation and cancer: implications for diagnosis and management. Pathol Oncol Res 2000;6:301-12.
31. Tesselar MET, Ouwerkerk J, Rosendaal FR, Osanto S. Prophylaxis with low molecular weight heparin reduces the risk for catheter-related venous thrombosis in cancer patients in centrally, but not in peripherally inserted central venous catheters (abstract). Proc Am Soc Clin Oncol 2001;19:1584.
32. Rösch TH. Endosonographic staging of gastric cancer: a review of literature results. Gastrointest Clin North Am 1995;3:549-57.
33. Siewert JR, Böttcher K, Bollschweiler E. Die TNM Klassifikation beim Magenkarzinom - das Problem der T2 Tumore. Dtsch Med Wochenschr 1991;116:473-5.
34. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000;88:921-32.
35. Siewert JR, Böttcher K, Stein HJ, Roder JD, Busch R. Problem of proximal third gastric carcinoma. World J Surg 1995;19:523-31.
36. UICC. TNM Classification of malignant tumours. 6th Ed. Berlin Tokyo Heidelberg New York: Springer-Verlag; 2002.
37. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
38. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87: 236-42.
39. Weiss M, Eder M, Bassermann R. Charakterisierung verschiedener Magenkarzinomtypen mit unterschiedlicher Metastasierung in Leber, Peritoneum und Knochen. Pathologe 1993; 14:260-4.
40. Hochwald SN, Kim S, Klimstra DS, Brennan MF, Karpeh MS. Analysis of 154 actual 5-year survivors of gastric cancer. J Gastrointest Surg 2000;4:520-5.